The growth in the historic period can be attributed to need for efficient pediatric immunization, government supported vaccination programs, proven safety of combination vaccines, rising pediatric healthcare access, success of dtap and ipv vaccines.
The growth in the forecast period can be attributed to expansion of booster dose coverage, increasing school immunization mandates, growth in pediatric healthcare spending, continued preference for combination vaccines, improved vaccine logistics. Major trends in the forecast period include growing adoption of combination pediatric vaccines, simplification of childhood immunization schedules, reduction in multiple injection burden, strengthening of routine booster vaccination programs, integration into school age immunization policies.
The growing demand for combination vaccines is expected to significantly drive the growth of the Kinrix market in the future. A combination vaccine is a single injection that provides protection against multiple diseases by including antigens for two or more pathogens, thus reducing the number of shots needed for immunization. The rising demand for combination vaccines is driven by factors such as enhanced vaccination coverage, lower costs, better compliance, and fewer injections. Kinrix is a combination vaccine used as a booster to protect children aged 4-6 years against diphtheria, tetanus, pertussis, and poliovirus, streamlining the immunization process and reducing the number of injections required. For example, in June 2024, Moderna, Inc., a U.S.-based clinical research organization, reported that as of May 2024, adults aged 18 and older in the U.S. received the 2023/2024 influenza vaccine at more than twice the rate of the updated COVID-19 vaccine. As a result, the increasing demand for combination vaccines is fueling the growth of the Kinrix market.
The rise in healthcare expenditure is expected to further propel the growth of the Kinrix market in the coming years. Healthcare expenditure encompasses spending on medical services, infrastructure, pharmaceuticals, and other healthcare-related activities. The increasing demand for healthcare services, driven by more individuals seeking preventive care and effective immunization solutions, is contributing to this growth. Kinrix supports vaccination programs by combining protection against multiple diseases in a single dose, reducing the need for multiple injections, saving time, and improving overall public health outcomes. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government agency, revealed that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. As a result, the rise in healthcare expenditure is driving the growth of the Kinrix market.
In May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, partnered with the Department of Health, Abu Dhabi (DoH), to establish a regional vaccine distribution hub in Abu Dhabi. This strategic collaboration, formalized through a Memorandum of Understanding (MoU), aims to enhance healthcare innovation and improve vaccine accessibility across the region. The Department of Health - Abu Dhabi (DoH) is a UAE-based government healthcare agency focused on promoting healthy living standards and increasing awareness and adoption of preventive healthcare measures among UAE residents.
Major companies operating in the kinrix market are GlaxoSmithKline plc.
North America was the largest region in the kinrix market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinrix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kinrix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the kinrix market by increasing costs for vaccine components, packaging materials, and international distribution. Pediatric clinics and public health departments in import reliant regions face higher procurement expenses. These pressures may affect vaccination program budgets and timelines. However, tariffs are encouraging domestic vaccine manufacturing and regional supply hubs. This supports long term stability of childhood immunization programs.
The kinrix market research report is one of a series of new reports that provides kinrix market statistics, including kinrix industry global market size, regional shares, competitors with a kinrix market share, detailed kinrix market segments, market trends and opportunities, and any further data you may need to thrive in the kinrix industry. This kinrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kinrix is a combination vaccine that provides protection against four diseases: diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It contains diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed (DTaP), and inactivated poliovirus vaccine (IPV). This vaccine streamlines immunization schedules by reducing the number of separate injections required, ensuring continued protection against these serious diseases in a convenient and efficient manner.
The main indications for Kinrix include vaccination against diphtheria, tetanus, pertussis, and poliomyelitis. Vaccination against diphtheria involves administering a toxoid vaccine to stimulate immunity, preventing severe respiratory infections caused by Corynebacterium diphtheriae. Kinrix is available in injectable formulations and pre-filled syringes, and is used for both pediatric and adult patient demographics. The vaccine is distributed through various channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is administered by various healthcare providers such as pediatric clinics, hospitals, family practice clinics, and public health departments.
The kinrix market consists of sales of pre-filled syringes or single-dose vials of kinrix (DTaP-IPV). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of booster dose coverage, increasing school immunization mandates, growth in pediatric healthcare spending, continued preference for combination vaccines, improved vaccine logistics. Major trends in the forecast period include growing adoption of combination pediatric vaccines, simplification of childhood immunization schedules, reduction in multiple injection burden, strengthening of routine booster vaccination programs, integration into school age immunization policies.
The growing demand for combination vaccines is expected to significantly drive the growth of the Kinrix market in the future. A combination vaccine is a single injection that provides protection against multiple diseases by including antigens for two or more pathogens, thus reducing the number of shots needed for immunization. The rising demand for combination vaccines is driven by factors such as enhanced vaccination coverage, lower costs, better compliance, and fewer injections. Kinrix is a combination vaccine used as a booster to protect children aged 4-6 years against diphtheria, tetanus, pertussis, and poliovirus, streamlining the immunization process and reducing the number of injections required. For example, in June 2024, Moderna, Inc., a U.S.-based clinical research organization, reported that as of May 2024, adults aged 18 and older in the U.S. received the 2023/2024 influenza vaccine at more than twice the rate of the updated COVID-19 vaccine. As a result, the increasing demand for combination vaccines is fueling the growth of the Kinrix market.
The rise in healthcare expenditure is expected to further propel the growth of the Kinrix market in the coming years. Healthcare expenditure encompasses spending on medical services, infrastructure, pharmaceuticals, and other healthcare-related activities. The increasing demand for healthcare services, driven by more individuals seeking preventive care and effective immunization solutions, is contributing to this growth. Kinrix supports vaccination programs by combining protection against multiple diseases in a single dose, reducing the need for multiple injections, saving time, and improving overall public health outcomes. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government agency, revealed that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. As a result, the rise in healthcare expenditure is driving the growth of the Kinrix market.
In May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, partnered with the Department of Health, Abu Dhabi (DoH), to establish a regional vaccine distribution hub in Abu Dhabi. This strategic collaboration, formalized through a Memorandum of Understanding (MoU), aims to enhance healthcare innovation and improve vaccine accessibility across the region. The Department of Health - Abu Dhabi (DoH) is a UAE-based government healthcare agency focused on promoting healthy living standards and increasing awareness and adoption of preventive healthcare measures among UAE residents.
Major companies operating in the kinrix market are GlaxoSmithKline plc.
North America was the largest region in the kinrix market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinrix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kinrix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the kinrix market by increasing costs for vaccine components, packaging materials, and international distribution. Pediatric clinics and public health departments in import reliant regions face higher procurement expenses. These pressures may affect vaccination program budgets and timelines. However, tariffs are encouraging domestic vaccine manufacturing and regional supply hubs. This supports long term stability of childhood immunization programs.
The kinrix market research report is one of a series of new reports that provides kinrix market statistics, including kinrix industry global market size, regional shares, competitors with a kinrix market share, detailed kinrix market segments, market trends and opportunities, and any further data you may need to thrive in the kinrix industry. This kinrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kinrix is a combination vaccine that provides protection against four diseases: diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). It contains diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed (DTaP), and inactivated poliovirus vaccine (IPV). This vaccine streamlines immunization schedules by reducing the number of separate injections required, ensuring continued protection against these serious diseases in a convenient and efficient manner.
The main indications for Kinrix include vaccination against diphtheria, tetanus, pertussis, and poliomyelitis. Vaccination against diphtheria involves administering a toxoid vaccine to stimulate immunity, preventing severe respiratory infections caused by Corynebacterium diphtheriae. Kinrix is available in injectable formulations and pre-filled syringes, and is used for both pediatric and adult patient demographics. The vaccine is distributed through various channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is administered by various healthcare providers such as pediatric clinics, hospitals, family practice clinics, and public health departments.
The kinrix market consists of sales of pre-filled syringes or single-dose vials of kinrix (DTaP-IPV). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Kinrix Market Characteristics
3. Kinrix Market Supply Chain Analysis
4. Global Kinrix Market Trends and Strategies
5. Kinrix Market Analysis of End Use Industries
7. Global Kinrix Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Kinrix Total Addressable Market (TAM) Analysis for the Market
9. Kinrix Market Segmentation
10. Kinrix Market Regional and Country Analysis
11. Asia-Pacific Kinrix Market
12. China Kinrix Market
13. India Kinrix Market
14. Japan Kinrix Market
15. Australia Kinrix Market
16. South Korea Kinrix Market
17. Western Europe Kinrix Market
18. UK Kinrix Market
19. Germany Kinrix Market
20. France Kinrix Market
21. Eastern Europe Kinrix Market
22. North America Kinrix Market
23. USA Kinrix Market
24. Canada Kinrix Market
25. South America Kinrix Market
26. Middle East Kinrix Market
27. Africa Kinrix Market
29. Kinrix Market Competitive Landscape and Company Profiles
32. Kinrix Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Kinrix Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses kinrix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kinrix? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kinrix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Vaccination Against Diptheria; Vaccination Against Tetanus; Vaccination Against Pertussis; Vaccination Against Poliomyelitis2) By Formulation: Injectable Formulation; Pre-filled Syringes
3) By Patient Demographics: Pediatric; Adult
4) By Distribution Channel: Direct Sales; Wholesalers And Distributors; Retail Pharmacies; Online Pharmacies
5) By End Users: Pediatric Clinics; Hospitals; Family Practice Clinics; Public Health Departments
Companies Mentioned: GlaxoSmithKline plc
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Kinrix market report include:- GlaxoSmithKline plc
